vs
科睿唯安（CLVT）与Penumbra Inc（PEN）财务数据对比。点击上方公司名可切换其他公司
科睿唯安的季度营收约是Penumbra Inc的1.6倍（$617.0M vs $385.4M），Penumbra Inc净利率更高（12.3% vs 0.5%，领先11.8%），Penumbra Inc同比增速更快（22.1% vs -6.9%），科睿唯安自由现金流更多（$89.2M vs $68.0M），过去两年Penumbra Inc的营收复合增速更高（17.6% vs -0.3%）
科睿唯安是一家英美合资的上市分析服务企业，主要提供订阅制信息服务，覆盖文献计量、科学计量、商业与市场情报领域，同时为医药、生物科技行业提供专利、监管合规相关的竞争分析，也提供商标保护、域名与品牌保护服务，旗下Web of Science产品系列还负责计算学术期刊的影响因子。
Penumbra Inc是2004年由Arani Bose与Adam Elsesser联合创立的美国医疗器械企业，总部位于加利福尼亚州阿拉米达，核心业务为研发、生产中风、动脉瘤等血管疾病介入治疗所用的专业医疗设备，产品已在全球多个国家的临床诊疗场景中投入使用。
CLVT vs PEN — 直观对比
营收规模更大
CLVT
是对方的1.6倍
$385.4M
营收增速更快
PEN
高出29.1%
-6.9%
净利率更高
PEN
高出11.8%
0.5%
自由现金流更多
CLVT
多$21.1M
$68.0M
两年增速更快
PEN
近两年复合增速
-0.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $617.0M | $385.4M |
| 净利润 | $3.1M | $47.3M |
| 毛利率 | 66.8% | 68.0% |
| 营业利润率 | 6.7% | 15.4% |
| 净利率 | 0.5% | 12.3% |
| 营收同比 | -6.9% | 22.1% |
| 净利润同比 | 101.6% | 40.6% |
| 每股收益（稀释后） | $0.00 | $1.20 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLVTPEN
| Q4 25 | $617.0M | $385.4M | ||
| Q3 25 | $623.1M | $354.7M | ||
| Q2 25 | $621.4M | $339.5M | ||
| Q1 25 | $593.7M | $324.1M | ||
| Q4 24 | $663.0M | $315.5M | ||
| Q3 24 | $622.2M | $301.0M | ||
| Q2 24 | $650.3M | $299.4M | ||
| Q1 24 | $621.2M | $278.7M |
净利润CLVTPEN
| Q4 25 | $3.1M | $47.3M | ||
| Q3 25 | $-28.3M | $45.9M | ||
| Q2 25 | $-72.0M | $45.3M | ||
| Q1 25 | $-103.9M | $39.2M | ||
| Q4 24 | $-191.8M | $33.7M | ||
| Q3 24 | $-65.6M | $29.5M | ||
| Q2 24 | $-304.3M | $-60.2M | ||
| Q1 24 | $-75.0M | $11.0M |
毛利率CLVTPEN
| Q4 25 | 66.8% | 68.0% | ||
| Q3 25 | 65.0% | 67.8% | ||
| Q2 25 | 67.2% | 66.0% | ||
| Q1 25 | 65.1% | 66.6% | ||
| Q4 24 | 65.7% | 66.8% | ||
| Q3 24 | 66.2% | 66.5% | ||
| Q2 24 | 67.2% | 54.4% | ||
| Q1 24 | 64.9% | 65.0% |
营业利润率CLVTPEN
| Q4 25 | 6.7% | 15.4% | ||
| Q3 25 | 7.1% | 13.8% | ||
| Q2 25 | 1.1% | 12.0% | ||
| Q1 25 | -3.5% | 12.4% | ||
| Q4 24 | -9.4% | 13.6% | ||
| Q3 24 | 3.5% | 11.7% | ||
| Q2 24 | -36.9% | -27.0% | ||
| Q1 24 | 0.8% | 4.3% |
净利率CLVTPEN
| Q4 25 | 0.5% | 12.3% | ||
| Q3 25 | -4.5% | 12.9% | ||
| Q2 25 | -11.6% | 13.3% | ||
| Q1 25 | -17.5% | 12.1% | ||
| Q4 24 | -28.9% | 10.7% | ||
| Q3 24 | -10.5% | 9.8% | ||
| Q2 24 | -46.8% | -20.1% | ||
| Q1 24 | -12.1% | 3.9% |
每股收益（稀释后）CLVTPEN
| Q4 25 | $0.00 | $1.20 | ||
| Q3 25 | $-0.04 | $1.17 | ||
| Q2 25 | $-0.11 | $1.15 | ||
| Q1 25 | $-0.15 | $1.00 | ||
| Q4 24 | $-0.27 | $0.88 | ||
| Q3 24 | $-0.09 | $0.75 | ||
| Q2 24 | $-0.46 | $-1.55 | ||
| Q1 24 | $-0.14 | $0.28 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $329.2M | $186.9M |
| 总债务越低越好 | $4.3B | — |
| 股东权益账面价值 | $4.8B | $1.4B |
| 总资产 | $11.1B | $1.8B |
| 负债/权益比越低杠杆越低 | 0.89× | — |
8季度趋势，按日历期对齐
现金及短期投资CLVTPEN
| Q4 25 | $329.2M | $186.9M | ||
| Q3 25 | $318.7M | $321.0M | ||
| Q2 25 | $362.6M | $421.8M | ||
| Q1 25 | $354.0M | $376.1M | ||
| Q4 24 | $295.2M | $324.4M | ||
| Q3 24 | $388.5M | $280.5M | ||
| Q2 24 | $376.4M | $288.3M | ||
| Q1 24 | $361.8M | $223.1M |
总债务CLVTPEN
| Q4 25 | $4.3B | — | ||
| Q3 25 | $4.4B | — | ||
| Q2 25 | $4.5B | — | ||
| Q1 25 | $4.5B | — | ||
| Q4 24 | $4.5B | — | ||
| Q3 24 | $4.6B | — | ||
| Q2 24 | $4.6B | — | ||
| Q1 24 | $4.6B | — |
股东权益CLVTPEN
| Q4 25 | $4.8B | $1.4B | ||
| Q3 25 | $4.9B | $1.4B | ||
| Q2 25 | $5.0B | $1.3B | ||
| Q1 25 | $5.0B | $1.2B | ||
| Q4 24 | $5.1B | $1.2B | ||
| Q3 24 | $5.5B | $1.1B | ||
| Q2 24 | $5.6B | $1.2B | ||
| Q1 24 | $5.9B | $1.2B |
总资产CLVTPEN
| Q4 25 | $11.1B | $1.8B | ||
| Q3 25 | $11.2B | $1.7B | ||
| Q2 25 | $11.4B | $1.7B | ||
| Q1 25 | $11.5B | $1.6B | ||
| Q4 24 | $11.5B | $1.5B | ||
| Q3 24 | $12.0B | $1.5B | ||
| Q2 24 | $12.1B | $1.5B | ||
| Q1 24 | $12.5B | $1.6B |
负债/权益比CLVTPEN
| Q4 25 | 0.89× | — | ||
| Q3 25 | 0.90× | — | ||
| Q2 25 | 0.90× | — | ||
| Q1 25 | 0.90× | — | ||
| Q4 24 | 0.88× | — | ||
| Q3 24 | 0.84× | — | ||
| Q2 24 | 0.83× | — | ||
| Q1 24 | 0.79× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $159.9M | $86.5M |
| 自由现金流经营现金流 - 资本支出 | $89.2M | $68.0M |
| 自由现金流率自由现金流/营收 | 14.5% | 17.7% |
| 资本支出强度资本支出/营收 | 11.5% | 4.8% |
| 现金转化率经营现金流/净利润 | 51.58× | 1.83× |
| 过去12个月自由现金流最近4个季度 | $365.3M | $174.9M |
8季度趋势，按日历期对齐
经营现金流CLVTPEN
| Q4 25 | $159.9M | $86.5M | ||
| Q3 25 | $181.1M | $58.3M | ||
| Q2 25 | $116.3M | $44.9M | ||
| Q1 25 | $171.2M | $49.0M | ||
| Q4 24 | $141.3M | $51.1M | ||
| Q3 24 | $202.9M | $56.5M | ||
| Q2 24 | $126.2M | $22.6M | ||
| Q1 24 | $176.2M | $38.3M |
自由现金流CLVTPEN
| Q4 25 | $89.2M | $68.0M | ||
| Q3 25 | $115.5M | $42.0M | ||
| Q2 25 | $50.3M | $29.4M | ||
| Q1 25 | $110.3M | $35.5M | ||
| Q4 24 | $59.1M | $45.7M | ||
| Q3 24 | $126.3M | $51.0M | ||
| Q2 24 | $60.3M | $18.1M | ||
| Q1 24 | $111.8M | $32.5M |
自由现金流率CLVTPEN
| Q4 25 | 14.5% | 17.7% | ||
| Q3 25 | 18.5% | 11.8% | ||
| Q2 25 | 8.1% | 8.7% | ||
| Q1 25 | 18.6% | 11.0% | ||
| Q4 24 | 8.9% | 14.5% | ||
| Q3 24 | 20.3% | 16.9% | ||
| Q2 24 | 9.3% | 6.0% | ||
| Q1 24 | 18.0% | 11.7% |
资本支出强度CLVTPEN
| Q4 25 | 11.5% | 4.8% | ||
| Q3 25 | 10.5% | 4.6% | ||
| Q2 25 | 10.6% | 4.6% | ||
| Q1 25 | 10.3% | 4.2% | ||
| Q4 24 | 12.4% | 1.7% | ||
| Q3 24 | 12.3% | 1.8% | ||
| Q2 24 | 10.1% | 1.5% | ||
| Q1 24 | 10.4% | 2.1% |
现金转化率CLVTPEN
| Q4 25 | 51.58× | 1.83× | ||
| Q3 25 | — | 1.27× | ||
| Q2 25 | — | 0.99× | ||
| Q1 25 | — | 1.25× | ||
| Q4 24 | — | 1.52× | ||
| Q3 24 | — | 1.91× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 3.48× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLVT
| Academia Government Group | $312.3M | 51% |
| Re Occurring Revenues | $114.1M | 18% |
| Life Sciences And Healthcare Group | $98.3M | 16% |
| Transactional Revenues | $97.1M | 16% |
PEN
| Thrombectomy | $254.7M | 66% |
| Other | $130.7M | 34% |
